12/16
01:05 pm
mgtx
Latest Published 5 Rare Eye Diseases Market Reports by DelveInsight: Retinitis Pigmentosa, Stargardt Disease, Ocular Melanoma, Uveitis, and Neurotrophic Keratitis [Yahoo! Finance]
Low
Report
Latest Published 5 Rare Eye Diseases Market Reports by DelveInsight: Retinitis Pigmentosa, Stargardt Disease, Ocular Melanoma, Uveitis, and Neurotrophic Keratitis [Yahoo! Finance]
12/12
08:52 am
mgtx
Investors in MeiraGTx Holdings (NASDAQ:MGTX) have unfortunately lost 71% over the last five years [Yahoo! Finance]
Low
Report
Investors in MeiraGTx Holdings (NASDAQ:MGTX) have unfortunately lost 71% over the last five years [Yahoo! Finance]
12/9
08:00 am
mgtx
MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia
Medium
Report
MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia
11/24
07:27 pm
mgtx
Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors
Medium
Report
Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors
11/18
05:39 pm
mgtx
MeiraGTx Holdings plc (NASDAQ: MGTX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $36.00 price target on the stock.
Medium
Report
MeiraGTx Holdings plc (NASDAQ: MGTX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $36.00 price target on the stock.
11/15
08:03 am
mgtx
MeiraGTx Holdings plc (NASDAQ:MGTX) Analysts Are Cutting Their Estimates: Here's What You Need To Know [Yahoo! Finance]
Low
Report
MeiraGTx Holdings plc (NASDAQ:MGTX) Analysts Are Cutting Their Estimates: Here's What You Need To Know [Yahoo! Finance]
11/14
12:07 pm
mgtx
MeiraGTx Holdings plc (NASDAQ: MGTX) had its price target raised by analysts at Royal Bank of Canada from $9.00 to $11.00. They now have an "outperform" rating on the stock.
Low
Report
MeiraGTx Holdings plc (NASDAQ: MGTX) had its price target raised by analysts at Royal Bank of Canada from $9.00 to $11.00. They now have an "outperform" rating on the stock.
11/13
08:00 am
mgtx
MeiraGTx Announces Third Quarter 2024 Financial and Operational Results and Recent Business Updates
Medium
Report
MeiraGTx Announces Third Quarter 2024 Financial and Operational Results and Recent Business Updates
11/7
07:05 pm
mgtx
Cramer's Lightning Round: Jabil is a buy [CNBC]
Low
Report
Cramer's Lightning Round: Jabil is a buy [CNBC]
10/22
08:00 am
mgtx
MeiraGTx Announces Five Posters at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress
Low
Report
MeiraGTx Announces Five Posters at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress
10/16
04:54 pm
mgtx
MeiraGTx's Parkinson's gene therapy shows promise in Phase I/II study [Yahoo! Finance]
Low
Report
MeiraGTx's Parkinson's gene therapy shows promise in Phase I/II study [Yahoo! Finance]
10/16
12:03 pm
mgtx
MGTX Stock Up on Upbeat Efficacy Data From Parkinson's Disease Study [Yahoo! Finance]
Low
Report
MGTX Stock Up on Upbeat Efficacy Data From Parkinson's Disease Study [Yahoo! Finance]
10/15
01:33 pm
mgtx
MeiraGTx: Positive PD Data Moves Needle Forward For Regulatory Meetings [Seeking Alpha]
Low
Report
MeiraGTx: Positive PD Data Moves Needle Forward For Regulatory Meetings [Seeking Alpha]
10/15
07:00 am
mgtx
MeiraGTx Announces Positive Data from Randomized, Sham-controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson’s Disease
High
Report
MeiraGTx Announces Positive Data from Randomized, Sham-controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson’s Disease
10/9
05:36 pm
mgtx
Cell and Gene Therapy in Parkinson's Disease Clinical Trial Pipeline Analysis Demonstrates 18+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight [Yahoo! Finance]
Low
Report
Cell and Gene Therapy in Parkinson's Disease Clinical Trial Pipeline Analysis Demonstrates 18+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight [Yahoo! Finance]
10/9
04:30 pm
mgtx
MeiraGTx Announces Poster Presentation on a Potential Treatment for MC4R Genetic Deficiency at the 2024 Society for Neuroscience Conference
Low
Report
MeiraGTx Announces Poster Presentation on a Potential Treatment for MC4R Genetic Deficiency at the 2024 Society for Neuroscience Conference
10/7
08:10 am
mgtx
MeiraGTx Holdings plc's (NASDAQ:MGTX) Profit Outlook [Yahoo! Finance]
Low
Report
MeiraGTx Holdings plc's (NASDAQ:MGTX) Profit Outlook [Yahoo! Finance]